JP2010532366A - ２−（３−｛６−［２−（２，４−ジクロロフェニル）−エチルアミノ］−２−メトキシピリミジン−４−イル｝−フェニル）−２−メチルプロピオン酸を製造する新しい方法 - Google Patents

２−（３−｛６−［２−（２，４−ジクロロフェニル）−エチルアミノ］−２−メトキシピリミジン−４−イル｝−フェニル）−２−メチルプロピオン酸を製造する新しい方法 Download PDF

Info

Publication number
JP2010532366A
JP2010532366A JP2010515021A JP2010515021A JP2010532366A JP 2010532366 A JP2010532366 A JP 2010532366A JP 2010515021 A JP2010515021 A JP 2010515021A JP 2010515021 A JP2010515021 A JP 2010515021A JP 2010532366 A JP2010532366 A JP 2010532366A
Authority
JP
Japan
Prior art keywords
phenyl
pyrimidin
chloro
methyl
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2010515021A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010532366A5 (enExample
Inventor
バオー−グオ・ファン
レダ・ジー・ハンナ
エリザベス・セコール
マシュー・アール・パワーズ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo SA filed Critical Sanofi Synthelabo SA
Publication of JP2010532366A publication Critical patent/JP2010532366A/ja
Publication of JP2010532366A5 publication Critical patent/JP2010532366A5/ja
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Catalysts (AREA)
JP2010515021A 2007-06-29 2008-06-24 ２−（３−｛６−［２−（２，４−ジクロロフェニル）−エチルアミノ］−２−メトキシピリミジン−４−イル｝−フェニル）−２−メチルプロピオン酸を製造する新しい方法 Abandoned JP2010532366A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94725607P 2007-06-29 2007-06-29
PCT/US2008/067963 WO2009006086A2 (en) 2007-06-29 2008-06-24 A new process for preparing 2-(3-{6-[2-(2,4-dichlorophenyl)-ethylamino]-2-methoxypyrimidin-4-yl}-phenyl)- 2-methylpropionic acid

Publications (2)

Publication Number Publication Date
JP2010532366A true JP2010532366A (ja) 2010-10-07
JP2010532366A5 JP2010532366A5 (enExample) 2011-07-21

Family

ID=40226759

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010515021A Abandoned JP2010532366A (ja) 2007-06-29 2008-06-24 ２−（３−｛６−［２−（２，４−ジクロロフェニル）−エチルアミノ］−２−メトキシピリミジン−４−イル｝−フェニル）−２−メチルプロピオン酸を製造する新しい方法

Country Status (11)

Country Link
US (1) US20100184979A1 (enExample)
EP (1) EP2170837B1 (enExample)
JP (1) JP2010532366A (enExample)
AR (1) AR067348A1 (enExample)
AT (1) ATE531699T1 (enExample)
CL (1) CL2008001913A1 (enExample)
PA (1) PA8786301A1 (enExample)
PE (1) PE20090428A1 (enExample)
TW (1) TW200922927A (enExample)
UY (1) UY31192A1 (enExample)
WO (1) WO2009006086A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5833626B2 (ja) * 2010-03-23 2015-12-16 サイノファーム タイワン リミテッド ラパチニブの調製プロセス及び中間体
CN104592137B (zh) * 2014-11-04 2016-09-14 江苏大学 2,2’,2”-[1,3,5-三嗪-2,4,6-三巯基]三丙酸及其合成方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN2005000795A (es) 2004-10-15 2010-08-19 Aventis Pharma Inc Pirimidinas como antagonistas del receptor de prostaglandina d2
GT200600457A (es) * 2005-10-13 2007-04-27 Aventis Pharma Inc Sal de fosfato dihidrogeno como antagonistas del receptor de prostaglandina d2
AR074776A1 (es) * 2008-12-18 2011-02-09 Sanofi Aventis Metodo para tratar la degeneracion macular; modulando el sistema inmunitario del paciente

Also Published As

Publication number Publication date
PA8786301A1 (es) 2009-01-23
EP2170837B1 (en) 2011-11-02
EP2170837A2 (en) 2010-04-07
US20100184979A1 (en) 2010-07-22
TW200922927A (en) 2009-06-01
WO2009006086A3 (en) 2009-03-12
ATE531699T1 (de) 2011-11-15
UY31192A1 (es) 2009-01-30
PE20090428A1 (es) 2009-05-04
AR067348A1 (es) 2009-10-07
WO2009006086A2 (en) 2009-01-08
CL2008001913A1 (es) 2009-01-16

Similar Documents

Publication Publication Date Title
JP5491589B2 (ja) 化学的プロセス
EP2408739B1 (en) A process for the preparation of 6-(7-((1-aminocyclopropyl)methoxy)-6-methoxyquinolin-4-yloxy)-n-methyl-1-naphthamide and synthetic intermediates thereof
CA3070069C (en) Improved process for preparing aminopyrimidine derivatives
JP7189932B2 (ja) タンパク質キナーゼに対する選択的阻害剤の合成に有用な中間体及びそれを調製するためのプロセス
JP6421172B2 (ja) マシテンタンの製造に有用なピリミジン中間体の製造
EP3166931A1 (en) An improved process for the preparation of enzalutamide
KR20190013554A (ko) 아미노피리미딘 유도체의 합성에 유용한 신규의 중간체, 이의 제조방법 및 이를 이용한 아미노피리미딘 유도체의 제조방법
RU2688665C2 (ru) Новый способ получения производных триазина, пиримидина и пиридина
JPH10139765A (ja) ピリミジン誘導体の製造方法
EP2331513A1 (en) Process for preparation of bosentan
JP2010532366A (ja) ２−（３−｛６−［２−（２，４−ジクロロフェニル）−エチルアミノ］−２−メトキシピリミジン−４−イル｝−フェニル）−２−メチルプロピオン酸を製造する新しい方法
SK285993B6 (sk) Spôsob výroby derivátov pyrimidínu substituovaných aminoskupinou a ich medziprodukty
WO1997043265A1 (en) Processes for the preparation of pyrimidine compound
EP0990647A1 (en) Process for producing quinolone derivatives
JP5516567B2 (ja) ４−アミノ−２−アルキルチオ−５−ピリミジンカルバルデヒドの製法
JP2005263673A (ja) ５−保護アミノピリミジン化合物の製造方法
KR101471047B1 (ko) 고순도 보센탄의 개선된 제조방법
CN105523958B (zh) 一种制备二芳基硫代乙内酰脲衍生物关键中间体的方法
JP5507147B2 (ja) ピリミジニルアルコール誘導体の製造方法及びその合成中間体
RU2804663C2 (ru) Способ получения двух 4-{ [(2s)-2-{ 4-[5-хлор-2-(1h-1,2,3-триазол-1-ил)фенил]-5-метокси-2-оксопиридин-1(2h)-ил} бутаноил]амино} -2-фторбензамидных производных
RU2654067C1 (ru) Способ получения 2-алкокси-6-[1-(2,6-дифторфенил)циклопропил]-5-метилпиримидин-4(3Н)-она
JP3527255B2 (ja) ６−ｎ−置換アミノピコリン酸誘導体及びその製造法
JPWO2010029756A1 (ja) ５−［２−（メチルチオ）エトキシ］ピリミジン−２−アミンの製造方法
Jagtap et al. Improved and single-pot process for the synthesis of macitentan, an endothelin receptor antagonist, via lithium amide-mediated nucleophilic substitution
WO2010012637A1 (en) Process for the preparation of bosentan

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110531

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110531

A762 Written abandonment of application

Free format text: JAPANESE INTERMEDIATE CODE: A762

Effective date: 20111215